HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup

Executive Summary

The agency issued a safety alert March 5 advising consumers to avoid three makeup products sold – at least previously – in Claire’s stores, which cater to girls and young women. The situation throws into relief the limitations of the current regulatory framework for cosmetics, which FDA is committed to modernizing while exploring steps to improve oversight using existing tools.

Advertisement

Related Content

Industry Cautions FDA To Avoid ‘Overinterpreting’ Cosmetic Allergy Survey Results
Claire’s Caves, Recalls Makeup Products Following FDA’s Asbestos Finding
House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform
Rep. Pallone’s Discussion Draft For Cosmetics Reform Closely Mirrors Reintroduced Feinstein/Collins Bill
With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives
J&J Doing Damage Control Following Reuters Report On Asbestos ‘Lurking’ In Johnson’s Powder
ICMAD Responds To Senate Proposal: Cosmetics Should Not Be Regulated Like Foods
‘Asbestos-Free’ A Relative Term? SAI Testing Expert On Cosmetic Talc Challenges
Senate Health Committee Releases Cosmetics Reform Discussion Draft
Claire's Scare Revives Concerns About Asbestos-Tainted Kids' Cosmetics

Topics

Advertisement
UsernamePublicRestriction

Register

RS148604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel